1. |
Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol, 2017, 31(10): 1616-1626.
|
2. |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018简版). 中华皮肤科杂志, 2019, 52(4): 223-230.
|
3. |
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res, 2011, 303(1): 1-10.
|
4. |
Bai F, Li GG, Liu Q, et al. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res, 2019, 2019: 2546161.
|
5. |
Lv J, Zhou D, Wang Y, et al. Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis. Mol Pain, 2018, 14: 1744806918762205.
|
6. |
Mahil SK, Ezejimofor MC, Exton LS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol, 2020, 183(4): 638-649.
|
7. |
Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One, 2019, 14(8): e0220868.
|
8. |
Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev, 2020, (1): CD011535.
|
9. |
Tada Y, Watanabe R, Noma H, et al. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci, 2020, 99(1): 53-61.
|
10. |
Xu G, Xia M, Jiang C, et al. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. J Pharmacol Sci, 2019, 139(4): 289-303.
|
11. |
Xu S, Gao X, Deng J, et al. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges, 2021, 19(1): 47-56.
|
12. |
Armstrong AW, Soliman AM, Betts KA, et al. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb), 2021, 11(3): 885-905.
|
13. |
Yasmeen N, Sawyer LM, Malottki K, et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat, 2022, 33(1): 204-218.
|
14. |
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Available at: http://handbook.cochrane.org.
|
15. |
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ, 2011, 342: d549.
|
16. |
Higgins JP, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods, 2012, 3(2): 98-110.
|
17. |
Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med, 2010, 29(7-8): 932-944.
|
18. |
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol, 2011, 64(2): 163-171.
|
19. |
栗梦婷, 朱鸿飞, 后亮瑛, 等. 网状Meta分析结论形成的方法: 最小背景化框架. 中国循证医学杂志, 2021, 21(9): 1102-1109.
|
20. |
王琪, 王建成, 潘蓓, 等. 网状Meta分析证据质量分级: GRADE方法学前沿与进展. 中国循证医学杂志, 2020, 20(8): 979-985.
|
21. |
Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol, 2007, 143(6): 719-726.
|
22. |
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 2007, 56(1): 31.e1-15.
|
23. |
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase 3, multicentre, double-blind trial. Lancet, 2005, 366(9494): 1367-1374.
|
24. |
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med, 2014, 371(4): 326-338.
|
25. |
Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl), 2020, 133(22): 2665-2673.
|
26. |
Ohtsuki M, Kubo H, Morishima H, et al. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol, 2018, 45(9): 1053-1062.
|
27. |
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371(9625): 1665-1674.
|
28. |
Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol, 2012, 39(3): 242-252.
|
29. |
Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol, 2018, 79(2): 302-314.
|
30. |
Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol, 2019, 46(8): 686-694.
|
31. |
Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol, 2015, 172(2): 484-493.
|
32. |
Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol, 2017, 31(5): 847-856.
|
33. |
Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol, 2019, 80(1): 70-79.
|
34. |
Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol, 2021, 35(1): 135-142.
|
35. |
Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol, 2017, 76(1): 60-69.
|
36. |
Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge):results from a phase Ⅲ, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol, 2021, 184(1): 50-59.
|
37. |
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, 2019, 394(10201): 831-839.
|
38. |
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med, 2016, 375(4): 345-356.
|
39. |
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase Ⅲ, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol, 2017, 76(3): 405-417.
|
40. |
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet, 2021, 397(10273): 487-498.
|
41. |
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med, 2015, 373(14): 1318-1328.
|
42. |
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet, 2018, 392(10148): 650-661.
|
43. |
Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb), 2020, 10(1): 73-86.
|
44. |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021). 中华皮肤科杂志, 2021, 54(12): 1033-1047.
|
45. |
Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase Ⅱ/Ⅲ randomized controlled study. J Dermatol, 2010, 37(4): 299-310.
|